<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954029</url>
  </required_header>
  <id_info>
    <org_study_id>ezClot1</org_study_id>
    <nct_id>NCT02954029</nct_id>
  </id_info>
  <brief_title>Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures</brief_title>
  <official_title>Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial access is the key step during the endovascular treatment of cardiovascular diseases.
      This study was designed to confirm the safety and efficacy of the hemostasis pad using
      chitosan in patients undergoing percutaneous procedures with arterial approach. Two cohorts
      will be included in this study: transradial and transfemoral cohort. Among the transfemoral
      cohort, the safety and efficacy of the ezClot pad will be compared with the BloodSTOP® pad
      (LifeScience PLUS, Palo Alto, CA, USA). The BloodSTOP® pad is an etherized and oxidized
      regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation
      pathway. The hypothesis will be tested among the transradial cohort that the combined use of
      a hemostasis pad and a compression device is superior to that of a compression device only in
      terms of hemostasis in patients who underwent tranradial coronary procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arterial access is the key step during the endovascular treatment of cardiovascular diseases.
      However, failure in hemostasis of the arterial access sites is associated with high risk of
      complications such as bleeding, pseudoaneurysm, and arteriovenous fistula. Major bleeding
      events after percutaneous coronary intervention has been shown be associated with poor
      short-term as well as long-term prognosis. Thus, there have been a variety of approaches to
      quickly and effectively achieve hemostasis of the puncture site. The traditional method was
      to apply manual compression followed by simple dressing directly on the puncture site.
      Despite a long history and economic advantage, this method required prolonged hemostasis
      time, substantial efforts by trained practitioner, and patients' discomfort.

      Use of hemostasis pad that accelerates blood clotting has become an effective alternative.
      The ezClot pad is a new product that uses chitosan, a deacetylated complex carbohydrate
      derived from the naturally occurring substance chitin. The positively charged chitosan
      molecules attract the negatively charged blood cells and platelets, thus promoting clots. The
      ability to hemostasis of chitosan has been proven with the HemCon® pad (HemCon Medical
      Technologies, Inc., Portland, OR, USA). This study was designed to confirm the safety and
      efficacy of the ezClot pad in patients undergoing percutaneous procedures with arterial
      approach. Two cohorts will be included in this study: transradial and transfemoral cohort.
      Among the transfemoral cohort, the safety and efficacy of the ezClot pad will be compared
      with the BloodSTOP® pad (LifeScience PLUS, Palo Alto, CA, USA). The BloodSTOP® pad is an
      etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating
      the intrinsic coagulation pathway.

      Transradial approach is increasing used during coronary procedures. The most important
      benefit of transradial approach compared to transfemoral approach is low risk of major
      bleeding. Widely used method for hemostasis of radial puncture sites were manual or
      device-assisted compression. There is yet only a limited data regarding the use of hemostasis
      pad after transradial approach. The hypothesis will be tested in the transradial cohort that
      the combined use of a hemostasis pad and a compression device is superior to that of a
      compression device only in terms of hemostasis in patients who underwent transradial coronary
      procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>Immediately after invasive procedures</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>within 24 hours</time_frame>
    <description>TIMI major/minor bleeding within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Hematoma within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retroperitoneal hematoma</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Retroperitoneal hematoma within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudoaneurysm</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Pseudoaneurysm within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel occlusion</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Vessel occlusion within 24 hours (either 1 or 2)
no palpable pulse
no flow on Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dissection</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Dissection of access vessel within 24 hours (either 1 or 2)
observed on angiography
symptomatic compromising distal flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical repair</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Surgical repair within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasovagal reaction</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Vasovagal reaction (grade 3-4) within 24 hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hb at discharge</measure>
    <time_frame>within 24 hours</time_frame>
    <description>hemoglobin (g/dL) within 24 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Hb at 1-month F/U</measure>
    <time_frame>1 month after discharge</time_frame>
    <description>hemoglobin (g/dL) at 1-month outpatient follow-up</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Puncture</condition>
  <arm_group>
    <arm_group_label>Study group (transradial cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>device-assisted compression with ezClot pad</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group (transfemoral cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>manual compression with ezClot pad</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (transradial cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rotary compression device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (transfemoral cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>manual compression with BloodSTOP ix pad</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ezClot (hemostasis pad)</intervention_name>
    <description>ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.</description>
    <arm_group_label>Study group (transradial cohort)</arm_group_label>
    <arm_group_label>Study group (transfemoral cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BloodSTOP ix pad</intervention_name>
    <description>BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.</description>
    <arm_group_label>Control group (transfemoral cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rotary compression device</intervention_name>
    <description>Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.</description>
    <arm_group_label>Study group (transradial cohort)</arm_group_label>
    <arm_group_label>Control group (transradial cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  patients undergoing invasive procedures via the radial or femoral arteries

        Exclusion Criteria:

          -  congenital or acquired bleeding tendency

          -  platelet count &lt;50,000/ μL

          -  hypersensitivity to shrimps, lobsters or beetles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>In-Ho Chae</last_name>
    <email>ihchae@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Si-Hyuck Kang</last_name>
    <phone>82-10-4011-5801</phone>
    <email>eandp303@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>06511</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Ho Chae</last_name>
      <email>ihchae@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Si-Hyuck Kang</last_name>
      <phone>82-10-4011-5801</phone>
      <email>eandp303@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011 Oct 18;58(17):1750-6. doi: 10.1016/j.jacc.2011.07.021.</citation>
    <PMID>21996385</PMID>
  </reference>
  <reference>
    <citation>Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006 Aug 22;114(8):774-82. Epub 2006 Aug 14.</citation>
    <PMID>16908769</PMID>
  </reference>
  <reference>
    <citation>Pusateri AE, Holcomb JB, Kheirabadi BS, Alam HB, Wade CE, Ryan KL. Making sense of the preclinical literature on advanced hemostatic products. J Trauma. 2006 Mar;60(3):674-82.</citation>
    <PMID>16531876</PMID>
  </reference>
  <reference>
    <citation>Arbel J, Rozenbaum E, Reges O, Neuman Y, Levi A, Erel J, Haskia AR, Caneti M, Sherf M, Mosseri M. USage of chitosan for Femoral (USF) haemostasis after percutaneous procedures: a comparative open label study. EuroIntervention. 2011 Apr;6(9):1104-9. doi: 10.4244/EIJV6I9A192.</citation>
    <PMID>21518684</PMID>
  </reference>
  <reference>
    <citation>Ferretti L, Qiu X, Villalta J, Lin G. Efficacy of BloodSTOP iX, surgicel, and gelfoam in rat models of active bleeding from partial nephrectomy and aortic needle injury. Urology. 2012 Nov;80(5):1161.e1-6. doi: 10.1016/j.urology.2012.06.048. Epub 2012 Aug 22.</citation>
    <PMID>22921708</PMID>
  </reference>
  <reference>
    <citation>Rathore S, Stables RH, Pauriah M, Hakeem A, Mills JD, Palmer ND, Perry RA, Morris JL. A randomized comparison of TR band and radistop hemostatic compression devices after transradial coronary intervention. Catheter Cardiovasc Interv. 2010 Nov 1;76(5):660-7. doi: 10.1002/ccd.22615.</citation>
    <PMID>20506228</PMID>
  </reference>
  <reference>
    <citation>Cong X, Huang Z, Wu J, Wang J, Wen F, Fang L, Fan M, Liang C. Randomized Comparison of 3 Hemostasis Techniques After Transradial Coronary Intervention. J Cardiovasc Nurs. 2016 Sep-Oct;31(5):445-51. doi: 10.1097/JCN.0000000000000268.</citation>
    <PMID>26002786</PMID>
  </reference>
  <reference>
    <citation>Dai N, Xu DC, Hou L, Peng WH, Wei YD, Xu YW. A comparison of 2 devices for radial artery hemostasis after transradial coronary intervention. J Cardiovasc Nurs. 2015 May-Jun;30(3):192-6. doi: 10.1097/JCN.0000000000000115.</citation>
    <PMID>24496325</PMID>
  </reference>
  <reference>
    <citation>Choi EY, Ko YG, Kim JB, Rhee J, Park S, Choi D, Jang Y, Shim WH, Cho SY. Hemostatic efficacy of hydrophilic wound dressing after transradial catheterization. J Invasive Cardiol. 2005 Sep;17(9):459-62.</citation>
    <PMID>16145231</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Si-Hyuck Kang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

